FAQ: Lantern Pharma's Presentation at ThinkEquity Conference and AI-Driven Oncology Drug Development

What is the main announcement in this content?

Lantern Pharma’s management team will present at the ThinkEquity Conference on Thursday, October 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York.

What does Lantern Pharma do?

Lantern Pharma is an artificial intelligence company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery using their proprietary AI and machine learning platform called RADR®.

What is RADR and how does it work?

RADR is Lantern Pharma’s proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to solve real-world problems in oncology drug development.

What is the significance of Lantern Pharma’s technology?

Their AI-driven approach accelerates the development of cancer therapies, reduces costs, and shortens timelines for oncology drug discovery, with their pipeline estimated to have a combined annual market potential of over $15 billion.

What types of cancer treatments is Lantern Pharma developing?

They are developing therapies that span multiple cancer indications including both solid tumors and blood cancers, plus an antibody-drug conjugate (ADC) program, with lead programs in Phase 2 and multiple Phase 1 clinical trials.

Where can investors find more information about Lantern Pharma?

The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN, and the full press release can be viewed at https://ibn.fm/QSF41.

What is the potential impact of Lantern Pharma’s work?

Their AI-driven pipeline has the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world while transforming the economics and efficiency of oncology drug development.

Who is distributing this press release and what services do they provide?

InvestorWire distributes this content and provides specialized communications services including wire-grade press release syndication, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.